Article info

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial
Free

Authors

  1. Correspondence to Professor Mikkel Østergaard, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen DK-2600, Denmark; mo{at}dadlnet.dk
View Full Text

Citation

Østergaard M, van Vollenhoven RF, Rudin A on behalf of the NORD-STAR study group, et al
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Publication history

  • Received March 5, 2023
  • Accepted June 7, 2023
  • First published July 9, 2023.
Online issue publication 
October 18, 2023
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.